Related Experiment Video
Updated: Apr 14, 2026
Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Sodium valproate induced necrotising pancreatitis: A case report
Insights
Sodium valproate, an epilepsy medication, can cause serious pancreatitis, especially in children and those with intellectual disabilities. Increased dosage may trigger this life-threatening condition, requiring careful monitoring and informed consent.
Area of Science:
- Neurology
- Gastroenterology
- Clinical Pharmacology
Background:
- Sodium valproate is a widely used first-line antiepileptic drug for generalized seizures.
- Its use requires careful consideration due to potential serious adverse events, including acute pancreatitis.
- Certain populations, like children and individuals with intellectual disabilities, may be at higher risk.
Observation:
- A case report details a 21-year-old male with intellectual disability presenting with acute abdominal symptoms.
- The patient experienced vomiting and diarrhea, necessitating emergency exploratory laparotomy.
- Intra-operative findings confirmed acute necrotizing pancreatitis.
Findings:
- The patient's recent increase in sodium valproate dosage is implicated as the likely cause of the pancreatitis.
- This case highlights a rare but severe complication associated with sodium valproate therapy.
- The severity of pancreatitis in this case underscores the need for vigilance.
Implications:
- Healthcare providers must be aware of the risk of sodium valproate-induced pancreatitis, particularly in vulnerable populations.
- Informed consent discussions should include potential life-threatening complications.
- Prompt diagnosis and management are crucial for patients presenting with suggestive symptoms during sodium valproate treatment.
Abstract:
Sodium valproate is one of the most common first-line antiepileptics prescribed for primary and secondary generalised seizures. However, serious complications associated with sodium valproate, such as acute pancreatitis, need to be considered when choosing this medication for treating epilepsy in certain populations such as children and persons with intellectual disability. We report a case of a 21-year-old man with intellectual disability who presented to the emergency department with an acute abdomen, vomiting and diarrhoea. He had to undergo an emergency exploratory laparotomy during which acute necrotising pancreatitis was diagnosed intra-operatively. We believe that the recent increase in sodium valproate dosage for his epilepsy was the cause of the pancreatitis. Carers of such persons should be adequately informed regarding possible life-threatening complications of medications prescribed to avoid delay in diagnosis and unwanted incidents.
